Clinical Trials Logo

Stage I Prostate Cancer AJCC v7 clinical trials

View clinical trials related to Stage I Prostate Cancer AJCC v7.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01251861 Active, not recruiting - Clinical trials for Recurrent Prostate Carcinoma

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Start date: December 23, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206 works in treating patients with previously treated prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether bicalutamide is more effective with or without Akt inhibitor MK2206 in treating prostate cancer.